![]() ![]() ![]() The use of CA125 alone in the diagnosis of ovarian cancer is therefore insufficient.įurthermore, the use of ultrasound alone or in combination with serum tumor biomarkers has been shown to be a better method of diagnosing adnexal masses. Additionally, the levels of CA125 vary in different subtypes of ovarian cancer. However, serum levels of CA125 have been shown to be increased not only in ovarian cancer but also in other pathological conditions or benign diseases such as pregnancy and endometriosis. Notably, cancer antigen 125 (CA125) is the most promising and significant marker in the screening, detection, and monitoring of ovarian cancer. Tumor biomarkers also play a vital role in the preoperative detection of ovarian cancer. ![]() However, the diagnostic performance of the O-RADS has not been validated therefore, its utilization still needs to be verified. This method therefore makes it easy for clinicians to classify adnexal masses because of its simplicity. IOTA SR is also easy to use, and nonexpert examiners can easily be trained on the technique. In addition, IOTA SR has been validated in multiple studies and has been shown to have the highest value in predicting preoperative differentiation of adnexal tumors. Moreover, several previous studies reported that US classification systems are highly effective in the detection of malignant ovarian cancer. Additionally, the Ovarian-Adnexal Reporting and Data System (O-RADS) was published by the American College of Radiology (ACR) and provides guidelines for ovarian management in high-risk categories. IOTA SR consists of five US features of benign tumors and five US features that can be used to identify malignant tumors. One such guideline that is extensively used in clinical practice is the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), which was proposed by the International Ovarian Tumor Analysis group in 200 8. Additionally, several guidelines and structured reporting based on ultrasound characterization have been proposed to help assess the risk of malignancy in ovarian masses. Ultrasound (US) is a non-invasive imaging method used in the identification of benign and malignant adnexal masses. Timely identification of malignant and benign ovarian tumors is therefore essential to guide therapeutic decisions and prognosis. It has also been reported that the 5-year survival rate of patients with late-stage ovarian cancer is < 50% (National Cancer Institute Cancer stat facts: ovarian cancer. In addition, most women with ovarian cancer are diagnosed at an advanced stage due to the lack of early symptoms related to the malignancy. Ovarian cancer is one of the deadliest gynecological tumors and one of the three most common malignancies in the female reproductive system. The findings showed that a combination of IOTA SR or O-RADS in combination with CA125 may improve the ability to distinguish benign from malignant ovarian tumors. The findings also showed that the AUCs of a combination of the three approaches were significantly higher than those of individual strategies ( p0.05). On the other hand, the AUCs of IOTA SR combined with CA125, O-RADS combined with CA125, and IOTA SR plus O-RADS combined with CA125 were 0.900, 0.891, and 0.909, respectively. In addition, the AUCs of IOTA SR, O-RADS, and CA125 in the overall population were 0.831, 0.804, and 0.812, respectively, and the sensitivities of IOTA SR, O-RADS, and CA125 were 94.42, 94.42, and 80.30%, respectively. Out of the 453 patients, 184 had benign lesions, while 269 had malignant ovarian tumors. Furthermore, the area under the curve (AUC), sensitivity, and specificity of the above mentioned predictors were calculated using the receiver operating characteristic curve. Additionally, all ultrasound images were independently assessed by two ultrasound physicians with more than 5 years of experience in the field, according to the IOTA simple rules and O-RADS guidelines. The data collected from patients included age, maximum lesion diameter, location, histopathology, levels of CA125, and detailed ultrasound reports. MethodsĪ total of 453 patients diagnosed with ovarian tumors were retrospectively enrolled from Fujian Cancer Hospital between January 2017 and September 2020. The study also assessed whether a combination of the two ultrasound categories systems and CA125 can improve the diagnostic performance. Therefore, the present study sought to determine the diagnostic performance of International Ovarian Tumor Analysis Simple Rules (IOTA SR), the Ovarian-Adnexal Reporting and Data System (O-RADS), and Cancer Antigen 125 (CA125) in discriminating benign and malignant ovarian tumors. Ovarian cancer is the most deadly deadliest gynecological tumor in the female reproductive system. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |